AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01481740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine infusion
Description: 60ml infusion of 100mcg/ml phenylephrine and placebo bolus
Study NCT04900480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct access to publicly subsidized physiotherapy
Description: This pilot project introduces temporary exemption on the legal required GP referral for public subsidy for treatment in general physiotherapy.
Study NCT01784354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure
Study NCT01784354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure dilatation
Study NCT01784354 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: education
Study NCT00614822 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin, Pemetrexed and Bevacizumab
Description: Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
Study NCT01527019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Study NCT01527019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporins
Description: Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Study NCT01527019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporins
Description: Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
Study NCT05910541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful breathing
Description: 30 minutes of mindful breathing session for 4 consecutive days, guided by investigators in addition to standard care.
Study NCT05910541 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care (control)
Description: Standard care such as pain control, oxygen supplement.
Study NCT05910541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care (control)
Description: Standard care such as pain control, oxygen supplement.
Study NCT04377061 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of anemia
Description: Evaluation of anemia in NCWS patients, and in CD and IBS controls, with both retrospective and prospective method.
Study NCT02980250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose
Description: 0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Study NCT02980250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal dose
Description: 0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Study NCT03448978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes-08
Description: autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
Study NCT03448978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: intravenous fludarabine
Study NCT03448978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: intravenous cyclophosphamide
Study NCT03373552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet function assay
Description: Platelet function assay
Study NCT04273399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-impact exercise intervention
Description: * Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading
Study NCT02980250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: over dose
Description: 0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Study NCT02980250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
Study NCT02964819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Study NCT02964819 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Study NCT04273399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-impact exercise intervention
Description: * Twelve-week high-impact exercise intervention~* Majority home based sessions, some supervised sessions~* Three exercise sessions per week~* Between 50 - 100 jumps per session~* Progressive jumping exercises to increase mechanical loading
Study NCT04273399 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acute response to high-impact exercise
Description: * First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise
Study NCT02964819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Study NCT02964819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interferential current therapy
Study NCT04273399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute response to high-impact exercise
Description: * First session of twelve-week high-impact exercise session used to assess the acute physiological response to one session of high-impact exercise in both Crohn's disease and healthy controls~* One supervised session of high-impact exercise~* Bloods to assess acute inflammatory and bone turnover response post-exercise
Study NCT02964819 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Ultrasound
Study NCT00752674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular balance
Study NCT00793026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd Breeze Pocket BR (Lactic Acid)
Description: Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
Study NCT02854059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IdeS (0.25 mg/kg)
Description: Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
Study NCT02854059 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IdeS (0.50 mg/kg)
Description: Single i.v. infusion of IdeS (0.50 mg/kg).
Study NCT03112980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation
Description: (TAVI)
Study NCT03112980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical aortic valve replacement
Description: (SAVR)
Study NCT00975962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actilyse
Description: Actilyse according to guidelines without pretreatment with remote persconditioning
Study NCT00975962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombolysis + remote perconditioning
Description: The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
Study NCT01449045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPTc+CCM
Description: Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
Study NCT01449045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Community Case Management with artemether-lumefantrine (AL)
Description: Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
Study NCT04859036 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hours ambulatory Holter monitoring
Study NCT04968860 — intervention group
Intervention type: OTHER
Intervention: This study is observational
Description: * Clinical evaluation of the oral health condition~* Microbiota evaluation by analyzing the collected saliva~* Application of questionnaires of quality of life
Study NCT01322646 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CarChipPro
Description: On board driving monitor
Study NCT01322646 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarChipPro
Description: On board driving monitor
Study NCT01322646 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Driver's Education
Description: 10 Session License to Learn Program.
Study NCT01322646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driver's Education
Description: 10 Session License to Learn Program.
Study NCT01322646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEER Program
Description: 8-session behavioral parent training and teen social skills/communication training program
Study NCT01322646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Driving Simulator Practice
Description: Practice Driving on a driving simulator
Study NCT01322646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Driving Simulator Practice
Description: Practice Driving on a driving simulator
Study NCT02859493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces cerevisiae
Study NCT02859493 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02603185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007
Study NCT02603185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01968954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg every 2 weeks, subcutaneous injection, 12 months
Study NCT01968954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, every 2 weeks for 12 months
Study NCT00803010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
Study NCT00803010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
Study NCT00803010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin (RAPA)
Description: Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
Study NCT02850991 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose
Description: Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
Study NCT02850991 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose
Description: Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
Study NCT03565055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPCST
Description: Integrative Psychosocial \& Community Skills Training (IPCST) programme~The IPCST programme includes:~1. psychoeducation, internalized stigma reduction, \& strength and coping enhancement~2. motivational interviewing skills~3. Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~4. augmented supported employment with social skills training (Tsang, Fung, Li, Leung \& Cheung, 2010) and~5. family and patient involvement in care
Study NCT03565055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E.A.S.Y
Description: The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~1. Extensive public education~2. Early referral and assessment~3. Ongoing treatment services
Study NCT00580944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser treatment of port wine stain birthmarks
Description: Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
Study NCT02985905 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc sulfate
Description: The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
Study NCT04251689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol 20 gram plus 0.9% normal saline 100 ml one hour after cisplatin
Study NCT04251689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline 100 ml
Study NCT01147575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine monohydrate
Description: The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
Study NCT01147575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
Study NCT02665364 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IFNα-Kinoid
Study NCT02665364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02665364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISA 51 VG
Study NCT02665364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ISA 51 VG
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
Study NCT00594789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information letters
Description: Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
Study NCT03740412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls
Description: The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
Study NCT03886142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency
Description: radiofrequency of the genicular nerves
Study NCT03886142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma injection
Description: intra articular injection of platelet rich plasma
Study NCT04658381 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Patient exome sequencing will be performed by Illumina technology on the NextSeq 550 sequencer. Briefly, the exons of the genes are selected by capture and are amplified by PCR simultaneously, in a single reaction, and then sequenced by Illumina technology. The analysis will only concern genes involved in albinism and in genetic pathologies associated with fovea plana.
Study NCT04658381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmologic exam
Description: Standard ophthalmologic assessment (measurement of visual acuity, measurement of intraocular pressure, slit lamp examination), OCT-B scan, OCT-Angiography, Adaptive optics
Study NCT03986008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benaglutide
Description: The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide
Description: 500 mg intravenous infusion every 2 weeks for 12 weeks
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 500 mg intravenous infusion every 2 weeks for 12 weeks
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azathioprine
Description: 2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: 2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: 60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
Study NCT03986008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abatacept placebo
Description: Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
Study NCT00774852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine placebo
Description: Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
Study NCT02063425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 1 pill of 20mg / day, during 3 months
Study NCT02063425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of fluoxetine
Description: 1 pill of 20mg/day, during 3 months
Study NCT03475316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Dancing
Description: 90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
Study NCT03475316 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Walking
Description: Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
Study NCT01504659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine hydrochloride injection
Description: Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.